{"id":"W4381612727","doi":"10.1200/jco.22.01599","title":"Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Melanoma; Oncology; Clinical trial; Confidence interval; Cancer; Immunotherapy; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003515584,0.0001455523,0.001411662,0.0001940038,0.00004276351,0.00000449865,0.0003263045,0.0002740576,0.0001489273],"category_scores_gemma":[0.002059689,0.00009089692,0.0007414775,0.0006294281,0.0002216479,0.00008107488,0.00008952407,0.0008765715,0.00001280994],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000226198,"about_ca_system_score_gemma":0.001568224,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005645562,"about_ca_topic_score_gemma":0.0003747782,"domain_scores_codex":[0.9959614,0.0005525126,0.002526491,0.0001959112,0.0004946549,0.0002690847],"domain_scores_gemma":[0.9958339,0.001965284,0.001487588,0.0003426989,0.0002278305,0.0001426942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6464722,0.005901374,0.04787516,0.00004027076,0.001380335,0.0007409999,0.001343541,0.00003197434,0.002608959,0.00003239145,0.00673596,0.2868368],"study_design_scores_gemma":[0.4983215,0.05706531,0.3956355,0.0001998732,0.0004829921,0.00009296902,0.003512282,0.00007090131,0.000433402,0.0001344678,0.04390024,0.000150589],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989336,0.0002553355,0.000003735074,0.003533871,0.004898727,0.000436812,0.000005464883,0.0000119447,0.001518149],"genre_scores_gemma":[0.9978507,0.0004963338,0.00009386005,0.0004156222,0.0004545842,0.000006822812,0.000001716684,0.00001928117,0.00066114],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3477603,"threshold_uncertainty_score":0.3808316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069024919856014,"score_gpt":0.472260736291704,"score_spread":0.3653582443061026,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}